Soquelitinib Overview - Soquelitinib is a first-in-class immune modulator with broad potential in cancer and immune diseases, targeting ITK [4, 5] - It has a novel mechanism of action with opportunities in oncology and immune diseases [5] - The drug has demonstrated a convenient oral dosing and attractive safety/tolerability profile in over 100 patients [5] - Corvus has strong IP protection with issued composition patents extending to November 2037 [5] Clinical Trials and Data - A randomized Phase 3 trial in PTCL is enrolling, with the potential for the first fully FDA-approved drug for PTCL [23, 24] - Phase 1 study in atopic dermatitis (AD) showed a significant reduction in EASI score at 28 days of treatment [68] - In the AD study, the 200 mg BID dose showed earlier and deeper responses, along with greater reductions in itch [68] - In AD Cohorts 1 and 2 (N=24), the mean EASI change was a 54.6% reduction, while in Cohort 3 (N=12), it was a 64.8% reduction, compared to a 34.4% reduction in the combined placebo group (N=12) [42] - In AD Cohort 3, 50% of patients with baseline PP-NRS ≥4 experienced a ≥ 4-point decrease in PP-NRS at Day 28 [53] Market and Future Development - The atopic dermatitis (AD) market is projected to reach $28 billion by 2030 [34] - Angel Pharma initiated a Phase 1b/2 trial in China for atopic dermatitis in Q4 2025 [59, 62] - Corvus anticipates data from the atopic dermatitis Phase 1 extension cohort 4 in January 2026 and plans to initiate a Phase 2 trial in early Q1 2026 [58, 69]

Financial Performance and Goals - PTC aims for a \$2 billion topline revenue through commercial launches and innovative R&D platforms[9],[48] - The company is focused on reaching cash flow breakeven without additional capital[11],[48] Sephience (Sepiapterin) for PKU - Sephience global launch has generated \$19.6 million in revenue, including \$14.4 million in the US and \$5.2 million ex-US[16] - 341 patients are on commercial Sephience therapy worldwide[16] - Sephience treatment resulted in a 63% mean blood Phe reduction in the overall primary analysis population compared to a 1% reduction with placebo (p<0.0001)[18] - In classical PKU patients, Sephience treatment resulted in a 69% mean blood Phe reduction compared to a 3% reduction with placebo (p<0.001)[18] - Sephience showed a 70.3% greater reduction in blood Phe concentration compared to sapropterin (BH4) (p < 0.0001)[24] Votoplam for Huntington's Disease - Novartis will provide a \$1 billion upfront payment for the votoplam collaboration[35] - PTC could receive up to \$1.9 billion in development, regulatory, and sales milestones from Novartis[35] - PTC will receive a 40% U S profit share and double-digit tiered royalties on ex-U S sales from Novartis[35] Vatiquinone for Friedreich's Ataxia - Vatiquinone demonstrated a 42% slowing (p=0.021) of disease progression in the Upright Stability score over 72 weeks compared to placebo[39] - Long-term extension studies showed a 50% slowing (p<0.0001) of disease progression over 3 years[40] - A 4.8-point benefit (p<0.0001) on mFARS over 2 years in ambulatory and non-ambulatory adults was observed[40]

Financial Performance - The company's Q3 2025 adjusted net income was $0.4 million, or $0.03 per share, a $0.01 increase per share compared to the same period in 2024[8] - Year-to-date adjusted net income reached $33.5 million, or $2.03 per share, a $1.4 million or $0.03 per share increase compared to the first nine months of 2024[8] - Adjusted gross margin increased by $4.7 million year-to-date for electric operations[25] - Adjusted gross margin for gas operations increased by $19.1 million year-to-date, driven by higher rates, customer growth, and colder weather[27] Acquisitions and Growth - Maine Natural Gas (MNG) acquisition closed on October 31, 2025, and Bangor Natural Gas (BNG) integration was completed[8, 10] - The combined price for BNG and MNG acquisitions was $157 million, with a combined rate base of $128 million and 15,100 customers[10] - Rate base is expected to grow by 10% including acquisitions[8] - Acquisitions are expected to accelerate long-term EPS and rate base growth, with an additional 17% in rate base and gas customers, and a 15% increase in gas margin[11] Capital Investments and Regulatory Updates - The company completed a utility-scale solar project in New Hampshire[13] - Advanced Metering Infrastructure (AMI) replacement is on schedule, with a combined capital investment of approximately $40 million[14, 17] - A temporary electric rate increase of $7.8 million took effect in Q3 2025 in New Hampshire[8] - The company's five-year projected capital investment is approximately $1.1 billion[43]

E N S I G N G R O U P INVESTOR PRESENTATION N o v e m b e r 2 0 2 5 w w w . e n s i g n g r o u p . n e t R: 105 G: 127 B: 87 #697F57 R: 172 G:200 B: 182 #ACC8B6 R: 0 G: 79 B: 103 #004F67 R: 153 G: 153 B: 204 #9999CC R: 252 G: 97 B: 92 #FC615C Primary Colors R: 0 G: 195 B: 255 #00C3FF R: 49 G: 131 B: 146 #008598 R: 68 G: 108 B: 120 # 446c78 R: 173 G: 106 B: 156 # b06a9b R: 148 G: 145 B: 147 #949193 R: 69 G: 110 B: 83 # 456E53 R: 41 G: 97 B: 99 # 296163 R: 47 G: 94 B: 84 # 2F5E54 Prevent Page Cut-off: File > ...

Financial Performance - YTD Q3 2025 Revenue reached €5542 million, a 77% increase at constant currency[11] - YTD Q3 2025 Adjusted EBITDA grew to €1358 million, an 112% increase at constant currency[11] - YTD Q3 2025 Free Cash Flow (pre-M&A) was €188 million, an increase of €257 million[11] - The company's leverage ratio decreased to 42x compared to the previous year[11] - Q3 2025 Net Revenue was €18654 million, a 40% increase[75] - YTD Group Profit reached €304 million, a 2454% increase[40] Business Segment Performance - Biopharma revenue increased by 91% YTD at constant currency, and 109% in Q3[45, 17] - IG (Immunoglobulin) franchise is a key driver of Biopharma growth, with overall growth ahead of the market[17] - Alpha-1 and specialty proteins also contributed to the growth of Biopharma[45] - Diagnostic revenue increased by 14% YTD at constant currency[45] Future Outlook - The company improved its revenue guidance for FY25 to €7600+ million at guidance FX rate[63] - The company improved its FCF pre-M&A pre-dividends guidance for FY25 to €400-425 million[63]

Q3 2025 Financial Performance - Total Adjusted EBITDDA reached $89.3 million, driven by strong Real Estate segment performance[10] - Timberlands Adjusted EBITDDA was $41.0 million, reflecting seasonally higher harvest volumes[10, 19] - Wood Products Adjusted EBITDDA was negative $(2.5) million, impacted by lower lumber prices[10] - Real Estate Adjusted EBITDDA significantly increased to $63.1 million due to rural real estate sales and increased Chenal Valley sales[10, 51] Timberlands Segment - Northern Timberlands Adjusted EBITDDA was $21.2 million with sawlog harvest volume at 403 thousand tons and an average price of $128 per ton[30] - Southern Timberlands Adjusted EBITDDA was $19.8 million with sawlog harvest volume at 614 thousand tons and an average price of $47 per ton[36] Wood Products Segment - Lumber shipment volume increased to 333 MMBF, but the average lumber price decreased by 12% to $396 per MBF[10, 44, 46] Real Estate Segment - Rural land sales involved 15,636 acres at an average price of $3,280 per acre[10, 53, 55] - Development segment sold 55 residential lots at an average price of $138,938 per lot and 13 commercial acres at $532,942 per acre[10, 53, 57] Capital Allocation and Liquidity - Cash Available for Distribution (CAD) was $118.5 million for the trailing twelve months[10] - The company maintains a strong liquidity position with $388 million available and a net debt to enterprise value of 23.1%[11]

Investor Presentation November 2025 In light of these factors, the events anticipated by Viper's forward-looking statements may not occur at the time anticipated or at all. Moreover, new risks emerge from time to time. Viper cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should ...

Company Overview - IIPR's total committed/invested capital is $2.5 billion[10] - The company owns 112 properties[10] - The weighted average lease length is 12.9 years[10] - Q3 2025 total revenue reached $64.7 million[10] - Over $1 billion in dividends have been paid since the company's inception in 2016[10] Portfolio Composition - Cannabis properties account for 95.3% of the portfolio[32] - Total annual income from cannabis properties is $315 million[32] - The top 10 states account for 89.6% of the annualized base rent (ABR), totaling $265.398 million[35] Financial Performance - The company has a debt to total gross assets ratio of 13%[57] - The debt service coverage ratio is 11.7x[58] - AFFO per share reached $6.84 annualized in Q3 2025, compared to $5.01 in 2020[64]

LKQ's Growth and Diversification - LKQ's total revenue has grown significantly from $328 million in 2003 to $12.8 billion in 2022 and $13.6 billion in Q3 2025 TTM[3] - LKQ has evolved from a North American collision operation to a globally diversified alternative parts distributor[3] - In Q3 2025 TTM, WNA-Recycled Products accounted for 15%, WNA-Aftermarket 18%, WNA-Hard Parts 45%, Europe Parts 14%, Specialty 6%, and Other 2% of total revenue[3] Market Position and Strategy - LKQ operates from a position of strength in its core markets, including Wholesale North America (~$6 billion) and LKQ Europe (~$6+ billion)[5,6] - LKQ's expertise lies in collision (aftermarket, recycled & refurbished, automotive paint), mechanical (recycled & remanufactured, hard parts), and services (vehicle diagnostics & calibration)[7] - LKQ's network effect results in a 75% fill rate, with 62% of parts revenue generated outside the yard but within the region, and 14% generated in another region[10] Strategic Priorities and Investment Thesis - Key strategic priorities include operational excellence, maximizing total stockholder return, and simplifying the business portfolio and operations[13] - LKQ aims to grow revenue organically faster than market growth and EBITDA faster than revenue[15] - LKQ focuses on cash flow and capital allocation to drive consistent and strong growth in Adjusted EPS over the long term[15] Collision Trends in North America - Unrepaired vehicles are increasing at a rate of 7% to 9% due to higher insurance rates and lower consumer confidence[17] - ELVs due to collision are increasing at a rate of 10% to 12% due to a decline in used car prices combined with increased cost to repair[17] - Insured TLVs are increasing at a rate of 3% to 5% due to higher deductibles, less insurance coverage, and increased concerns about rising insurance premiums[17]

Financial Performance - Q3 2025 diluted EPS was $1.86[10], compared to $2.03 in Q3 2024[12], a decrease of 8%[12] - Year-to-date 2025 diluted EPS was $5.32[12], compared to $5.87 in the same period of 2024[12], a decrease of 9%[12] - The company increased the 2025 EPS guidance midpoint to $6.47[10], a 3% increase[13] - The company's ROE (trailing twelve months) was 16% on an equity layer of 64%[10] Electric Platform - The company filed a Minnesota rate case requesting a net revenue increase of $44.8 million, a 17.7% increase, with a proposed ROE of 10.65% and an equity layer of 53.5%[16] - The company filed a South Dakota rate case requesting a net revenue increase of $5.7 million, a 12.5% increase, with a proposed ROE of 10.8% and an equity layer of 53.54%[19] - The company updated the rate base growth CAGR to 10%[10], with significant rate base growth from $1.89 billion in 2024 to $3.41 billion in 2030[22] Manufacturing Platform - Sales prices in the plastics segment decreased by 17% quarter-to-date and 14% year-to-date, while sales volumes increased by 4% quarter-to-date and 9% year-to-date[41] - The company is undertaking a multi-phase expansion project at Vinyltech Corporation, which is expected to increase plastics segment production capacity by 15% upon completion of Phase 1 and 2[46] - BTD Georgia expansion is expected to generate up to $35 million in incremental annual revenue[46] Investment and Growth - The company increased the long-term EPS growth rate target to 7-9% (2028 base year)[10] - The company's capital expenditure plan includes $1.918 billion for the electric segment and $129 million for manufacturing & plastics from 2026 to 2030[63] - The company targets a total shareholder return of 10-12%, a dividend yield of ~3%, and a dividend growth rate of 6-8%[69]